No data to show
XASX
OSX
Market cap1mUSD
May 21, Last price
0.01AUD
1D
-6.67%
1Q
-50.00%
IPO
-99.48%
Name
Osteopore Ltd
Chart & Performance
P/E
—
P/S
0.86
EPS
—
Div Yield, %
—
Shrs. gr., 5y
123.88%
Rev. gr., 5y
46.68%
Revenues
3m
+26.79%
Net income
-3m
L-33.40%
CFO
-3m
L-16.82%
Earnings
May 30, 2025
Profile
Osteopore Limited designs, develops, and markets bioresorbable polymer implants for neurosurgical, orthopedic, and maxillofacial surgery applications in Singapore, Australia, and internationally. Its technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. The company offers Osteoplug, a bioresorbable implant, which is used for covering trephination burr holes in neurosurgery; and Osteomesh, a bioresorbable implant that is used in craniofacial surgery to repair various types of fractures, such as orbital floor fracture, as well as to fill surgical defects. Osteopore Limited has a collaboration agreement with Livingstone Health Holding Limited to jointly develop new applications and products for regenerating bone and tissue. The company was incorporated in 2003 and is headquartered in Singapore.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | 2,811 26.79% | 2,217 24.51% | 1,781 26.80% | ||||||
Cost of revenue | 5,266 | 6,086 | 7,381 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (2,455) | (3,869) | (5,600) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 571 | 44 | 20 | ||||||
Tax Rate | |||||||||
NOPAT | (2,456) | (3,912) | (5,620) | ||||||
Net income | (3,245) -33.40% | (4,872) 15.57% | (4,216) 7.30% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 3,116 | 2,349 | 891 | ||||||
BB yield | -82.31% | -34.46% | -27.19% | ||||||
| Debt | |||||||||
Debt current | 1,221 | 1,093 | 45 | ||||||
Long-term debt | 277 | 29 | 103 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 860 | (35) | (2,017) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (3,108) | (3,737) | (3,997) | ||||||
CAPEX | (15) | (7) | (64) | ||||||
Cash from investing activities | (15) | (7) | (64) | ||||||
Cash from financing activities | 2,630 | 3,579 | 842 | ||||||
FCF | (2,835) | (3,315) | (5,511) | ||||||
| Balance | |||||||||
Cash | 638 | 1,157 | 2,165 | ||||||
Long term investments | |||||||||
Excess cash | 498 | 1,046 | 2,076 | ||||||
Stockholders' equity | 434 | 433 | 2,107 | ||||||
Invested Capital | 1,331 | 1,093 | 105 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 108,156 | 57,766 | 8,238 | ||||||
Price | 0.04 -70.34% | 0.12 -70.34% | 0.40 -33.33% | ||||||
Market cap | 3,785 -44.47% | 6,816 108.01% | 3,277 -29.75% | ||||||
EV | 4,645 | 6,781 | 1,260 | ||||||
EBITDA | (1,924) | (3,404) | (5,382) | ||||||
EV/EBITDA | |||||||||
Interest | 426 | 15 | 20 | ||||||
Interest/NOPBT | |||||||||